Mad Money's Jim Cramer reflects on CNBC's evolution over the past 25 years.» Read More
The CEO of this dying newspaper company is a one-man black hole for shareholder value.
This waste management play is money in the bank so long as Romano is at the helm.
Surprise, surprise. Another CEO could get a massive payout despite his terrible performance.
There's an opportunity to make money, and Cramer doesn't want investors missing it.
I'm in the press room at the midtown Manhattan hotel where Pfizer is holding its analyst meeting. There's just over half a dozen reporters here and we're nearly outnumbered by PR folks. As one of them remarked, the press turnout for an event like this just isn't what it used to be...
Here's something that should make you realize what crazy times we are living in: 9-year auto loans are popping up around the country. That's right, it wasn't a typo. Nine years! 108 months! Almost a third of the time used to pay off a conventional mortgage!
The day before Pfizer's analyst meeting tomorrow investors are not showing much love for the beaten-down Dow component. PFE's trading in the early going today at its lowest level since December 2005.
Amid the gloomy comments from auto executives at the Geneva Motor Show, the unveilings of several important new models are being overshadowed. Take the new Ford Fiesta. This compact car is being sold in Europe, but the design cues and architecture behind this car will be the underpinnings of compact cars the automaker will roll out in the U.S. in the future.
Expensive oil and a coal shortage will only push this stock higher, Cramer says.
On the eve of the make-or-break Texas-Ohio primaries for Sen. Hillary Clinton, she remains in first place in at least one "poll." The Center for Responsive Politics has updated its list of top pharmaceuticals/health products-industry money recipients based on the most recent campaign finance reports and the former First Lady edges out Sen. Barack Obama...
Fortress Investment Group came to market at private equity's peak. Too bad no one but the company knew the party was over.
It's Cramer's favorite of his Fab Five agriculture stocks. Don't miss this interview with the CEO.
Only 39 percent of big investors think the way U.S. companies reward top executives has helped improve corporate performance, and most believe that top managers have too much influence in setting their own pay, a new study has found.
German drugs and chemicals group Bayer missed fourth-quarter earnings expectations Thursday, sending shares 4.7 percent lower on the DAX, but CEO Werner Wenning told CNBC he remains optimistic about the company’s outlook for this year.
When Schering-Plough Chairman and CEO Fred Hassan recently decided to buy another $2 million worth of SGP shares in the wake of the Vytorin study takedown, the company put out a press release.
Recently I've blogged and raised the question in an interview about whether Onyx Pharmaceuticals might be having a tough time finding a new leader. Well, nearly six months since longtime Chairman and CEO Hollings Renton announced his plans to retire this year, the biotech company has filled the spot.
This company's turned a "trifecta of negativity" into pure positivity.
A tough fourth quarter sunk the stock. But Ray Milchovich doesn't want people giving up yet.
With the stock price recently cut in half, Cramer has some concerns. Find out how the chief executive responded.
Austrian oil and gas group OMV reported on Tuesday a forecast-beating 23 percent increase in clean operating earnings in the fourth quarter on favourable crude prices and improved refining margins.